Cytori reports summary of FDA feedback regarding its ATI-1123 product (Cytori Press Release) - Jul 1, 2019 - "Cytori Therapeutics...provided an update on the development of its proprietary drug, ATI-1123, based on recently obtained feedback from the United States Food and Drug Administration (FDA)....ATI-1123 has completed a phase I trial. Based on the FDA feedback, the Company plans to proceed with a follow-on phase II trial in platinum-sensitive small cell lung cancer who have progressed at least 60 days after initiation of first-line chemotherapy."
FDA event • New P2 trial
|